Open this publication in new window or tab >>Linköping University, Department of Physics, Chemistry and Biology, Computational Biology . Linköping University, The Institute of Technology.
Rosetta Inpharmatics, LLC, a Merck & Co., Inc, Seattle, USA.
The Computational Medicine Group, Atherosclerosis Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
The Computational Medicine Group, Atherosclerosis Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden/Clinical Gene Networks AB, Karolinska Science Park, Stockholm, Sweden.
Linköping University, Department of Physics, Chemistry and Biology, Computational Biology . Linköping University, The Institute of Technology.
Linköping University, Department of Physics, Chemistry and Biology, Computational Biology . Linköping University, The Institute of Technology.
South African National Bioinformatics Institute (SANBI), University of the Western Cape, Cape Town, South Africa, and Computational Bioscience Research Center (CBRC), King Abdullah University of Science and Technology (KAUST), Thuwal, Kingdom of Saudi Arabia.
Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Cardiovascular Genetics Group, Atherosclerosis Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Massachusetts General Hospital (MGH) Weight Center and Department of Medicine, Harvard Medical School, Boston, USA.
Department of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Physiology, Stockholm Söder Hospital, Karolinska Institutet, Stockholm, Sweden.
Department of Thoracic Surgery and Anesthesiology, Karolinska University Hospital and Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Department of Thoracic Surgery and Anesthesiology, Karolinska University Hospital and Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Department of Surgery, Stockholm Söder Hospital, Karolinska Institutet, Stockholm, Sweden.
Department of Surgery, Stockholm Söder Hospital, Karolinska Institutet, Stockholm, Sweden.
Department of Thoracic Surgery and Anesthesiology, Karolinska University Hospital and Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Rosetta Inpharmatics, LLC, a Merck & Co., Inc, Seattle, USA.
Department of Thoracic Surgery and Anesthesiology, Karolinska University Hospital and Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Cardiovascular Genetics Group, Atherosclerosis Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Linköping University, Department of Physics, Chemistry and Biology, Computational Biology . Linköping University, The Institute of Technology.
The Computational Medicine Group, Atherosclerosis Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden/Clinical Gene Networks AB, Karolinska Science Park, Stockholm, Sweden 4 Rosetta Inpharmatics, LLC, a Merck & Co., Inc, Seattle, USA.
Show others...
2009 (English)In: PLoS Genetics, ISSN 1553-7390, Vol. 5, no 12, p. e1000754-Article in journal (Refereed) Published
Abstract [en]
Environmental exposures filtered through the genetic make-up of each individual alter the transcriptional repertoire in organs central to metabolic homeostasis, thereby affecting arterial lipid accumulation, inflammation, and the development of coronary artery disease (CAD). The primary aim of the Stockholm Atherosclerosis Gene Expression (STAGE) study was to determine whether there are functionally associated genes (rather than individual genes) important for CAD development. To this end, two-way clustering was used on 278 transcriptional profiles of liver, skeletal muscle, and visceral fat (n=66/tissue) and atherosclerotic and unaffected arterial wall (n=40/tissue) isolated from CAD patients during coronary artery bypass surgery. The first step, across all mRNA signals (n=15,042/12,621 RefSeqs/genes) in each tissue, resulted in a total of 60 tissue clusters (n=3958 genes). In the second step (performed within tissue clusters), one atherosclerotic lesion (n=49/48) and one visceral fat (n=59) cluster segregated the patients into two groups that differed in the extent of coronary stenosis (P=0.008 and P=0.00015). The associations of these clusters with coronary atherosclerosis were validated by analyzing carotid atherosclerosis expression profiles. Remarkably, in one cluster (n=55/54) relating to carotid stenosis (P=0.04), 27 genes in the two clusters relating to coronary stenosis were confirmed (n=16/17, P<10-27and-30). Genes in the transendothelial migration of leukocytes (TEML) pathway were overrepresented in all three clusters, referred to as the atherosclerosis module (A-module). In a second validation step, using three independent cohorts, the A-module was found to be genetically enriched with CAD risk by 1.8-fold (P<0.004). The transcription co-factor LIM domain binding 2 (LDB2) was identified as a potential high-hierarchy regulator of the A-module, a notion supported by subnetwork analysis, cellular and lesion expression of LDB2, and the expression of 13 TEML genes in Ldb2-deficient arterial wall. Thus, the A-module appears to be important for atherosclerosis development and together with LDB2 merits further attention in CAD research.
Place, publisher, year, edition, pages
PLoS Genetics, 2009
National Category
Natural Sciences
Identifiers
urn:nbn:se:liu:diva-52084 (URN)10.1371/journal.pgen.1000754 (DOI)
Note
On the day of the defence day the status of this article was: In Press.2009-12-032009-12-032009-12-07Bibliographically approved